Accurate and rapid performance of medical diagnostic tests is a critical requirement for molecular diagnosis and disease treatment. While immunoassays are used in the majority of in vitro diagnostics, limitations such as cross-reactivity, low sensitivity, and limited dynamic range, compel clinical laboratories to seek better solutions that are highly sensitive, reproducible and specific, while also providing high throughput.
Recent advancements in new analytical methods and techniques over the last decade, specifically mass spectrometry (MS)-based targeted proteomic analytical methods and techniques, now allow for the highly reproducible and precise measurement of nearly every human protein. Nevertheless, translating these methods and techniques into ‘clinical grade’ assays presents many challenges.
We invite submissions for this special issue that focuses on the clinical translation of targeted MS proteomics and associated technologies. The scope includes, but is not limited to, the areas listed below:
• MS-based targeted proteomics methodologies, such as selected/multiple reaction monitoring (S/MRM) and parallel reaction monitoring (PRM). The reported methods could be MS hardware- or software-based.
• MS-based targeted proteomics assay resources.
• Development, testing, and validation of targeted assays for measuring protein expression, post-translational modifications (PTMs) and protein functions to aid in the diagnosis and/or monitoring of human diseases.
• Standardization of targeted proteomics methodologies for clinical applications, such as MS data acquisition, data formats, quality control, internal and external standards, metrological analysis, and other clinical translation issues.
• Non-MS-based targeted proteomics with clinical potential.
Research articles, technical notes, reviews, and commentaries are all examples of article types.